1/2 life of semaglutide **remember percentages of weight loss vary depending on the population A new study suggests GLP-1s

5, 2023 from McLenon, J

PubMed laboratory research record [PMID: 34964141] PubMed record related to this compound for laboratory literature review

(2013), High protein intake stimulates postprandial GLP1 and PYY release

Theyre losing weight at a controlled pace instead of racing to the lowest number

Published phase 2 data provide preliminary signals regarding tolerability in research cohorts, but these are not sufficient to establish a safety profile adequate for approved use

No comparable large-scale trials exist for semaglutide powder drinks because no regulated pharmaceutical product in that format has been formally studied for weight loss indication